No Data
No Data
No Data
No Data
No Data
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced s
GlobeNewswireMar 26 20:00
Ayala Completes Patient Enrollment for Pivotal Desmoid Tumor Study
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, has announced the completion of patient enrollment for its Phase 3 RINGSIDE study, which is evaluating the efficacy of the drug AL102 in treating desmoid tumors.
Investing.com Feb 20 23:32
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment h
GlobeNewswireFeb 20 21:00
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating.
MT NewswiresFeb 7 21:53
Advaxis Announces Definitive Agreement With Ayala Pharmaceuticals
TipRanksFeb 7 17:17
Immunome Shares Rise 16% After Acquisition of Potential Tumor Treatment From Ayala Pharmaceuticals
By Chris Wack Immunome shares were up 16% to $19.56 after the company agreed to buy AL102 and related drug candidate AL101 from Ayala Pharmaceuticals. Ayala shares more than doubled to $1.31 in rece
WSJFeb 6 23:53
No Data
No Data